US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Articles published by Metsera, Inc.

News headline image
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera to Present at Upcoming September Investor Conferences
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera to Present at Bank of America 2025 Global Healthcare Conference
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
From Metsera, Inc.
Via GlobeNewswire
Tickers MTSR
News headline image
Metsera Announces Pricing of Initial Public Offering
From Metsera, Inc.
Via GlobeNewswire
News headline image
Metsera Announces Positive Topline Phase 2a Clinical Data for its Ultra-Long Acting GLP-1 Receptor Agonist, MET-097i
From Metsera, Inc.
Via Business Wire
News headline image
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio
From Metsera, Inc.
Via Business Wire